BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 103 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,416 | -62.0% | 1,350 | 0.0% | 0.00% | – |
Q2 2023 | $8,991 | -64.3% | 1,350 | 0.0% | 0.00% | -100.0% |
Q1 2023 | $25,191 | -39.8% | 1,350 | 0.0% | 0.00% | -50.0% |
Q4 2022 | $41,823 | +178.8% | 1,350 | 0.0% | 0.00% | +100.0% |
Q3 2022 | $15,000 | -11.8% | 1,350 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $17,000 | -39.3% | 1,350 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $28,000 | +3.7% | 1,350 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $27,000 | -18.2% | 1,350 | +25.0% | 0.00% | 0.0% |
Q3 2021 | $33,000 | +6.5% | 1,080 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $31,000 | -34.0% | 1,080 | 0.0% | 0.00% | -50.0% |
Q1 2021 | $47,000 | +9.3% | 1,080 | +15.5% | 0.00% | 0.0% |
Q4 2020 | $43,000 | +4.9% | 935 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $41,000 | -18.0% | 935 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $50,000 | +316.7% | 935 | +76.1% | 0.00% | +100.0% |
Q1 2020 | $12,000 | +50.0% | 531 | 0.0% | 0.00% | – |
Q4 2019 | $8,000 | +100.0% | 531 | 0.0% | 0.00% | – |
Q3 2019 | $4,000 | -33.3% | 531 | 0.0% | 0.00% | – |
Q2 2019 | $6,000 | – | 531 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
APIS CAPITAL ADVISORS, LLC | 40,000 | $836,000 | 1.01% |
ACT CAPITAL MANAGEMENT, LLC | 20,000 | $418,000 | 0.44% |
Knoll Capital Management, LLC | 20,000 | $418,000 | 0.26% |
Artemis Investment Management LLP | 1,428,228 | $29,855,000 | 0.24% |
Rubric Capital Management LP | 268,528 | $5,615,000 | 0.20% |
Virtus ETF Advisers LLC | 7,713 | $161,000 | 0.07% |
BOOTHBAY FUND MANAGEMENT, LLC | 107,700 | $2,252,000 | 0.05% |
PDT Partners, LLC | 28,031 | $586,000 | 0.05% |
AllSquare Wealth Management LLC | 3,162 | $66,000 | 0.04% |
Hennion & Walsh Asset Management, Inc. | 35,221 | $736,000 | 0.04% |